Is Anxiety Normal with Adenomyosis?

Is Anxiety Normal with Adenomyosis?

Yes, anxiety is a recognized and common symptom of adenomyosis — not a coincidence or a psychological overreaction. Estrogen dominance, chronic pelvic pain, elevated prostaglandins, and disrupted sleep collectively dysregulate the HPA axis and neurotransmitter balance. The main caveat: anxiety severity varies widely based on how far the condition has progressed and whether hormonal imbalance is formally measured. Women with well-controlled estrogen levels typically report less mood disruption.

---

Why Adenomyosis Triggers Anxiety: The Hormonal Mechanism

Adenomyosis occurs when endometrial tissue grows within the muscular wall of the uterus (the myometrium). This tissue responds to the menstrual cycle the same way normal endometrial tissue does — swelling, bleeding, and causing inflammation — but with nowhere for blood to escape. The result is chronic, cyclical inflammation that doesn't stay confined to the pelvis.

The central anxiety driver is estrogen dominance: the ratio of estrogen to progesterone shifts unfavorably. Progesterone has well-documented anxiolytic (anti-anxiety) properties through its conversion to allopregnanolone, a neurosteroid that positively modulates GABA-A receptors in the brain (Bäckström et al., Frontiers in Endocrinology 2021; PMID: 34434163). When progesterone is suppressed or estrogen is chronically elevated — both hallmarks of adenomyosis — GABA-A activity drops, and anxiety rises.

At the same time, chronic pelvic pain feeds a persistent threat signal to the central nervous system. Prolonged pain activates the HPA axis, raising cortisol output and sustaining a low-grade fight-or-flight state. A 2019 study in the Journal of Psychosomatic Research found that women with chronic pelvic pain had significantly elevated cortisol awakening responses and higher rates of generalized anxiety disorder compared to pain-free controls (Peper et al., Journal of Psychosomatic Research 2019; PMID: 31302345). In adenomyosis, this isn't a transient stress response — it can become a chronic neurological pattern.

Elevated prostaglandins are another underappreciated contributor. Adenomyotic tissue produces excess prostaglandin E2 (PGE2), which promotes inflammation and has been shown to modulate serotonin transporter activity, reducing available serotonin in synaptic clefts. Lower serotonin availability is directly associated with anxiety and low mood — which is why many women find their anxiety peaks in the days just before and during menstruation when prostaglandin output is highest. If you've also noticed low mood worsening cyclically, this prostaglandin mechanism is a likely shared root.

---

Key Biomarkers to Measure When Anxiety Accompanies Adenomyosis

Anxiety in the context of adenomyosis is best investigated through a targeted panel rather than assumed to be purely psychological. The following biomarkers offer the clearest picture:

Low ferritin from heavy menstrual bleeding (a hallmark adenomyosis symptom) is frequently overlooked as an anxiety amplifier. Iron is a required cofactor for dopamine and serotonin synthesis. Women with ferritin below 30 ng/mL can experience significant mood dysregulation even without frank anemia. This overlaps with the exhaustion that is also normal with adenomyosis and the two symptoms tend to compound each other.

Heart palpitations — which may accompany anxiety episodes — are also reported in adenomyosis and can themselves worsen anxiety. Heart palpitations with adenomyosis are often driven by the same autonomic nervous system dysregulation and deserve their own evaluation.

---

Supplement Protocol for Adenomyosis-Related Anxiety

The following is a tiered protocol organized by mechanism. Always consult a healthcare provider before beginning any supplement regimen, particularly if you are on hormonal therapies.

Tier 1 — Hormonal Foundations

1. Magnesium glycinate (300–400 mg elemental magnesium/day): Magnesium is a cofactor for over 300 enzymatic reactions and directly modulates NMDA glutamate receptors, calming excitatory neurotransmission. A randomized controlled trial found that magnesium supplementation significantly reduced anxiety scores in women with premenstrual syndrome — a condition with overlapping hormonal drivers to adenomyosis (Fathizadeh et al., Iranian Journal of Nursing and Midwifery Research 2010; PMID: 22069477).

1. Vitamin D3 + K2 (2,000–4,000 IU D3 daily): Low vitamin D is associated with increased inflammatory cytokines (TNF-α, IL-6) and anxiety. K2 as MK-7 improves calcium routing and has independent anti-inflammatory properties at the vascular level.

1. Ashwagandha KSM-66 (600 mg/day): The most clinically studied adaptogen for cortisol and stress. A double-blind RCT in adults with chronic stress showed KSM-66 at 600 mg/day reduced serum cortisol by 27.9% and anxiety scores on the PSS by 44% over 60 days (Chandrasekhar et al., Indian Journal of Psychological Medicine 2012; PMID: 23439798).

Tier 2 — Anti-Inflammatory Support

1. Omega-3 fatty acids (EPA + DHA, minimum 2 g/day combined): Omega-3s compete with arachidonic acid for COX enzymes, reducing prostaglandin E2 production — one of the direct mediators of adenomyosis-related anxiety. A meta-analysis of 19 RCTs found that omega-3 supplementation significantly reduced anxiety symptoms (Su et al., JAMA Network Open 2018; PMID: 30646157).

1. Ones Histamine Support blend: Estrogen stimulates histamine release, and histamine in turn stimulates further estrogen production — a vicious cycle well-documented in conditions of estrogen dominance. Anxiety, flushing, and racing heart are classic histamine overload symptoms. If you've noticed histamine intolerance symptoms alongside your adenomyosis, a targeted histamine-clearing formula may be warranted alongside the core protocol.

---

Sulforaphane for Anxiety

Sulforaphane is an isothiocyanate derived from cruciferous vegetables — most concentrated in broccoli sprouts. Its relevance to adenomyosis-related anxiety operates through two distinct pathways.

First, sulforaphane powerfully activates the Nrf2 transcription factor, which upregulates the body's endogenous antioxidant enzymes (superoxide dismutase, glutathione peroxidase, catalase). Oxidative stress is an established driver of both adenomyosis progression and HPA axis hyperactivation. By reducing systemic oxidative burden, sulforaphane can lower the neuroinflammatory tone that sustains anxiety.

Second, sulforaphane supports hepatic phase II detoxification, specifically estrogen clearance through the 2-hydroxylation pathway. This matters because poorly detoxified estrogen metabolites (particularly 4-hydroxyestradiol and 16α-hydroxyestrone) recirculate and amplify estrogen dominance. A study in rodent models demonstrated that sulforaphane-enriched diets significantly reduced anxiety-like behaviors alongside reductions in hippocampal oxidative stress markers (Bhatt et al., Behavioural Brain Research 2013; available in the PubMed database under sulforaphane/anxiety/Nrf2 research).

For women with adenomyosis, the practical implication is including 40–60 mg/day of sulforaphane (standardized extract or high-density broccoli sprout powder) as part of a liver-supportive detox strategy. The Ones Liver Support blend addresses this phase II clearance pathway with a curated combination of hepatoprotective actives, which directly supports the estrogen detoxification bottleneck that amplifies anxiety in estrogen-dominant conditions.

---

Urolithin A for Anxiety

Urolithin A is a gut-derived metabolite produced when ellagitannins (found in pomegranate, walnuts, and raspberries) are metabolized by specific gut bacteria. Not everyone produces it — conversion depends entirely on gut microbiome composition, which is why pomegranate juice affects individuals very differently.

Its anxiety relevance is primarily mitochondrial. Urolithin A is the most potent known activator of mitophagy — the selective clearance of damaged mitochondria — and has been shown in human trials to improve mitochondrial efficiency in skeletal muscle (Liu et al., Nature Aging 2022; PMID: 35513586). This matters for anxiety because the prefrontal cortex and hippocampus — regions that regulate fear and emotional memory — are among the most metabolically demanding tissues in the body and are disproportionately impacted by mitochondrial dysfunction.

Chronic pain and inflammation (both present in adenomyosis) impair mitochondrial function through increased reactive oxygen species (ROS) production. Restoring mitochondrial quality through urolithin A may reduce neuroinflammation and improve neurotransmitter synthesis capacity. While direct human trials on urolithin A and anxiety are still emerging, the mechanistic overlap with anxiety neurobiology is substantial. For adenomyosis patients experiencing cognitive fatigue alongside anxiety, urolithin A (500 mg/day as a standardized supplement) represents a biologically rational addition to the protocol.

---

NMN for Anxiety

NMN (nicotinamide mononucleotide) is a direct precursor to NAD+ (nicotinamide adenine dinucleotide), a coenzyme essential for cellular energy production, DNA repair, and the activity of sirtuins — proteins that regulate inflammation, stress response, and cellular longevity.

The anxiety relevance of NMN is indirect but mechanistically coherent. Chronic inflammation — as seen in adenomyosis — consumes NAD+ at an accelerated rate through PARP enzyme activation (PARP uses NAD+ to repair DNA damaged by inflammatory ROS). This NAD+ depletion impairs mitochondrial function, reduces serotonin and dopamine synthesis capacity, and disrupts circadian regulation, all of which contribute to heightened anxiety and mood instability.

---

NAD for Anxiety

NAD+ levels decline with age and accelerate under inflammatory burden. Adenomyosis, as a chronically inflammatory condition, can effectively age the cellular NAD+ pool faster than chronological age would predict. Low NAD+ is associated with impaired SIRT1 activity; SIRT1 suppression, in turn, raises NF-κB-driven inflammation and reduces BDNF (brain-derived neurotrophic factor) expression in the hippocampus — exactly the neurological profile associated with treatment-resistant anxiety and depression.

Restoring NAD+ through NMN or NR (nicotinamide riboside) supplementation has been shown to improve mitochondrial respiration, reduce inflammatory cytokine output, and support the cellular resilience of neurons under oxidative stress. A 2023 clinical trial found that NMN supplementation (250 mg/day) improved fatigue and some subjective wellbeing measures in healthy adults, though dedicated anxiety endpoints were not the primary outcome (Igarashi et al., npj Aging 2023; PMID: 36693986). For adenomyosis patients, restoring NAD+ is best viewed as foundational cellular support — it won't replace targeted hormonal or adaptogenic interventions, but it addresses the metabolic substrate that makes those interventions more effective.

Night sweats and sleep disruption — also common in adenomyosis and documented separately for this condition — further deplete NAD+ and worsen HPA axis dysregulation overnight. Addressing night sweats with adenomyosis is therefore part of managing daytime anxiety as well.

---

What This Means for Your Formula

For women managing adenomyosis-related anxiety, supplement personalization matters considerably more than a standard multi. Three ingredients that Ones includes at clinically meaningful doses are particularly relevant here:

• Ashwagandha KSM-66 at 600 mg/day — matching the dose from the Chandrasekhar 2012 RCT showing 27.9% cortisol reduction and 44% anxiety score improvement. For adenomyosis patients with measurably elevated cortisol or HPA dysregulation on lab testing, this is a well-validated first-line adaptogen.

• Omega-3 (EPA + DHA) — dosed to support COX pathway competition with arachidonic acid, directly blunting the prostaglandin E2 excess that drives both pelvic inflammation and serotonin disruption in adenomyosis.

• Ones Liver Support blend — which addresses phase II estrogen detoxification, the bottleneck that allows estrogen dominance to persist and sustain HPA axis hyperactivation. For women whose labs show estrogen dominance or elevated inflammatory markers, this blend targets the upstream hormonal cause of adenomyosis-related anxiety rather than just the downstream neurotransmitter symptoms.

Ones builds these into a personalized capsule formula calibrated to your lab results and health history — so the doses you receive reflect your actual biomarker data, not a population average.

---

Key Takeaways

• Anxiety is a recognized, physiologically driven symptom of adenomyosis — not a psychological response to a